Yılmaz Ufuk, Yasar Zehra, Korkmaz Esra, Yalcın Burcu, Koparal Hakan, Ozbilek Engin
Department of Chest Diseases, Suat Seren Chest Disease and Surgery Training and Research Hospital, İzmir, Turkey.
Chest Diseases, Medistate Kavacık Hospital, İstanbul, Turkey.
Med Glas (Zenica). 2017 Aug 1;14(2):204-210. doi: 10.17392/898-17.
Aim Concurrent chemoradiotherapy (CRT) is the standard of care for locally advanced, unresectable non-small cell lung carcinoma (NSCLC). The aim of this study was to assess the prognostic value of maximum standardized uptake values (SUVmax) in patients with unresectable stage III NSCLC treated with concurrent CRT. Method 18F-FDG PET-CT scans were obtained before and after treatment in patients with unresectable stage III NSCLC treated with concurrent CRT. To determine the prognostic value of SUVmax of the primary tumor (PT), univariate and multivariate Cox regression model were carried out. Results Between January 2008 and December 2013, this study included 43 patients (median age 56 years, 95% male). Univariate analysis showed that having a high post-treatment PT-SUVmax was associated with a higher risk of death and having a high post-treatment PT-SUVmax with a higher risk of disease recurrence. Multivariate analysis showed that having a low post-treatment PTSUVmax (cut off 3.9) was associated with longer overall and progression free survival (HR 8.55, 95% CI; 2.56-28.55, p=0.000 and HR 2.854, 95% CI; 1.43-5.67, p=0.003, respectively). Conclusion Post-treatment PT-SUVmax may be an independent prognostic factor in patients with unresectable stage III NSCLC treated with concurrent chemoradiotherapy.
目的 同步放化疗（CRT）是局部晚期、不可切除非小细胞肺癌（NSCLC）的标准治疗方法。本研究旨在评估同步放化疗治疗的不可切除Ⅲ期NSCLC患者中最大标准化摄取值（SUVmax）的预后价值。方法 对接受同步放化疗的不可切除Ⅲ期NSCLC患者在治疗前和治疗后进行18F-FDG PET-CT扫描。为确定原发肿瘤（PT）的SUVmax的预后价值，进行单因素和多因素Cox回归模型分析。结果 2008年1月至2013年12月，本研究纳入43例患者（中位年龄56岁，95%为男性）。单因素分析显示，治疗后PT-SUVmax高与死亡风险较高相关，治疗后PT-SUVmax高与疾病复发风险较高相关。多因素分析显示，治疗后PT-SUVmax低（截断值3.9）与更长的总生存期和无进展生存期相关（HR 8.55，95%CI：2.56 - 28.55，p = 0.000；HR 2.854，95%CI：1.43 - 5.67，p = 0.003）。结论 治疗后PT-SUVmax可能是同步放化疗治疗的不可切除Ⅲ期NSCLC患者的独立预后因素。
